Evidence map›Paper›PMID 38235614›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Metabolic Bypass Rescues Aberrant S-nitrosylation-Induced TCA Cycle Inhibition and Synapse Loss in Alzheimer's Disease Human Neurons.

Alexander Y Andreyev, Hongmei Yang, Paschalis-Thomas Doulias, Nima Dolatabadi, Xu Zhang, Melissa Luevanos, Mayra Blanco, Christine Baal, Ivan Putra, Tomohiro Nakamura and 3 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Glutamine metabolism in health and disease.Signal transduction and targeted therapy · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Metabolic modulation of TCA cycle bySynthetic and systems biotechnology · 2026
    Article
  9. Review
  10. Article
  11. Review
  12. Open medicine (Warsaw, Poland) · 2026
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Redox modulation of the complement cascade contributes to synapse loss in Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Alexander Y AndreyevDepartment of Molecular Medicine and Neurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Hongmei YangDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Paschalis-Thomas DouliasChildren's Hospital of Philadelphia Research Institute and Departments of Pediatrics and Pharmacology, Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
Nima DolatabadiDepartment of Molecular Medicine and Neurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Xu ZhangDepartment of Molecular Medicine and Neurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Melissa LuevanosDepartment of Molecular Medicine and Neurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Mayra BlancoDepartment of Molecular Medicine and Neurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Christine BaalDepartment of Molecular Medicine and Neurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Ivan PutraDepartment of Molecular Medicine and Neurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Tomohiro NakamuraDepartment of Molecular Medicine and Neurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Harry IschiropoulosChildren's Hospital of Philadelphia Research Institute and Departments of Pediatrics and Pharmacology, Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
Steven R TannenbaumNortheast Asia Institute of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, 130021, China.
Stuart A LiptonDepartment of Molecular Medicine and Neurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0002-3490-1259
Scripps Research Institute · USChangchun University of Chinese Medicine · CNChildren's Hospital of Philadelphia · US

Funding

UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JAMES B BREWER · 2019 to 2026
$34.9M
Novel Proteomics Approach to HIV-Associated Neurocognitive Disorder & Drug AbuseDP1DA041722 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2016 to 2020
$7.0M
Leadership in AD/ADRD Drug DiscoveryR35AG071734 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2021 to 2025
$5.4M
Omics Analyses of HIV and Substance Use DisorderR01DA048882 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI REPUNTE-CANONIGO, VEZ · 2019 to 2023
$4.3M
Dynamic Interactions of the S-Nitrosoproteome in Type 2 Diabetes/Metabolic Syndrome and Alzheimer’s DiseaseRF1AG057409 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2017 to 2020
$4.1M
S-Nitrosylation-Induced Posttranslational Modification and Aberrant Cell Signaling in Sporadic Alzheimer's DiseaseR01AG056259 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2017 to 2021
$3.3M
Aberrant protein S-nitrosylation mediates Gene-Environment Interactions in AD/ADRDU01AG088679 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI STUART A LIPTON, Tomohiro Nakamura · 2024 to 2026
$2.7M
Neuroprotective Mechanisms of S-Nitrosylated ApoE2 in Aging and Alzheimer's DiseaseR01AG061845 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI NAKAMURA, TOMOHIRO · 2018 to 2022
$2.4M
Crosstalk between innate-immunity human microglia and adaptive-immunity Tregs in Alzheimer's diseaseR01AG078756 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI STUART A LIPTON · 2022 to 2026
$2.3M
Identification and Verification of S-Nitrosylated Proteins in Bodily Fluids as Biomarkers for Parkinson's Disease and Lewy Body DementiaR61NS122098 · NINDS · SCRIPPS RESEARCH INSTITUTE, THE · PI NAKAMURA, TOMOHIRO · 2021 to 2021
$2.2M
S-Nitrosylation-Dependent Pathological Spread of Abnormal Proteins in Frontotemporal Dementia and Lewy Body DementiaRF1NS123298 · NINDS · SCRIPPS RESEARCH INSTITUTE, THE · PI NAKAMURA, TOMOHIRO · 2021 to 2021
$2.1M
Pro-Electrophilic Drugs PEDs for Alzheimer's DiseaseR56AG065372 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2020 to 2021
$1.8M
NIA NIH HHS P30 AG062429NIA NIH HHS R01 AG056259NIA NIH HHS R01 AG061845NIA NIH HHS R01 AG078756NIA NIH HHS R35 AG071734NIA NIH HHS R56 AG065372NIA NIH HHS RF1 AG057409NIA NIH HHS U01 AG088679NIDA NIH HHS DP1 DA041722NIDA NIH HHS R01 DA048882NIH HHS DP1 DA041722NIH HHS R01 AG056259NIH HHS R01 AG061845NIH HHS R01 DA048882NIH HHS R35 AG071734NIH HHS R56 AG065372NIH HHS R61 NS122098NIH HHS RF1 AG057409NIH HHS RF1 NS123298NINDS NIH HHS R01 NS123298NINDS NIH HHS R61 NS122098NINDS NIH HHS RF1 NS123298
6 · The paper itself

Abstract

In Alzheimer's disease (AD), dysfunctional mitochondrial metabolism is associated with synaptic loss, the major pathological correlate of cognitive decline. Mechanistic insight for this relationship, however, is still lacking. Here, comparing isogenic wild-type and AD mutant human induced pluripotent stem cell (hiPSC)-derived cerebrocortical neurons (hiN), evidence is found for compromised mitochondrial energy in AD using the Seahorse platform to analyze glycolysis and oxidative phosphorylation (OXPHOS). Isotope-labeled metabolic flux experiments revealed a major block in activity in the tricarboxylic acid (TCA) cycle at the α-ketoglutarate dehydrogenase (αKGDH)/succinyl coenzyme-A synthetase step, metabolizing α-ketoglutarate to succinate. Associated with this block, aberrant protein S-nitrosylation of αKGDH subunits inhibited their enzyme function. This aberrant S-nitrosylation is documented not only in AD-hiN but also in postmortem human AD brains versus controls, as assessed by two separate unbiased mass spectrometry platforms using both SNOTRAP identification of S-nitrosothiols and chemoselective-enrichment of S-nitrosoproteins. Treatment with dimethyl succinate, a cell-permeable derivative of a TCA substrate downstream to the block, resulted in partial rescue of mitochondrial bioenergetic function as well as reversal of synapse loss in AD-hiN. These findings have therapeutic implications that rescue of mitochondrial energy metabolism can ameliorate synaptic loss in hiPSC-based models of AD.

Indexed as

Alzheimer DiseaseInduced Pluripotent Stem CellsEnergy MetabolismGlycolysisHumansNeuronsAlzheimer's diseasesS‐nitrosylationtricarboxylic acid cycles

Identifiers

PMID38235614
PMCPMC10966553
OpenAlexW4390979492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.